Eyenovia Inc

+0.04 (+1.15%)
Products, Regulatory, Other Pre-Announcement

Bausch Health Licenses Eyenovia's Investigational Treatment For Reduction Of Pediatric Myopia Progression In Children

Published: 10/12/2020 13:49 GMT
Eyenovia Inc (EYEN) - Bausch Health Licenses Eyenovia's Investigational Treatment for the Reduction of Pediatric Myopia Progression in Children Ages 3-12.
Bausch Health Companies - Affiliate Acquired License for Development, Commercialization of Investigational Formulation of Atropine Ophthalmic Solution.
Bausch Health Companies Inc - Bausch Health Will Make an Upfront $10 Million Payment to Eyenovia Upon Signing.
Bausch Health Companies Inc - Will Assume Oversight and Costs Related to Ongoing Phase 3 Chaperone Clinical Trial.
Bausch Health Companies Inc - Eyenovia Eligible to Receive Up to $35 Million in Additional Payments Based on Approval- and Launch-based Milestones.
Bausch Health Companies - Eyenovia Eligible to Receive Royalties Ranging From Mid-single Digit to Mid-teen Percentages of Gross Profit on Sales.